Precision medicine is increasingly defined by how early disease can be detected—and how intelligently risk can be stratified. Tempus AI, Inc. (NASDAQ: TEM) has announced a collaboration with Median Technologies (EPA: ALMDT) to integrate Median’s eyonis® LCS into the Tempus Pixel platform, expanding AI-powered lung cancer screening capabilities across the U.S. The move brings together... Read More









